Taiwan
· Delayed Price · Currency is TWD Foresee Pharmaceuticals Company Description
Foresee Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in the United States, China, and Europe.
The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases.
Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases.
Foresee Pharmaceuticals Co., Ltd. was incorporated in 2013 and is based in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Benjamin Chien |
Contact Details
Address: No. 19-3, Sanchong Road Taipei, 115 Taiwan | |
| Phone | 886 2 7750 0188 |
| Website | foreseepharma.com |
Stock Details
| Ticker Symbol | 6576 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006576002 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Benjamin Chien Ph.D. | Founder, Chief Executive Officer and Chairman |
| Dr. Yuhua Li Ph.D. | Co-founder and Chief Technology Officer |
| Dr. Mathieu Boudreau Ph.D. | Chief Business Officer and Chief Operating Officer |
| Dr. Wenjin Yang Ph.D. | Chief Scientific Officer, Co-Acting Head of Clinical Development and Vice President |
| Dr. Yisheng Lee Ph.D. | Chief Medical Officer, Acting Head of Clinical Development and Representative Director |
| Dr. Jagdish Parasrampuria Ph.D. | Senior Vice President of Pharmaceutics and Manufacturing |
| MengKung Chan | Chief Financial Officer |
| Liang Chris | Accounting Officer |
| Dr. John Mao | Consultant |
| Peifen Chou | Consultant |